Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.

Feng B, LaPerle JL, Chang G, Varma MV.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):939-52. doi: 10.1517/17425255.2010.482930. Review.

PMID:
20433402
2.

Membrane transporters in drug development.

International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L.

Nat Rev Drug Discov. 2010 Mar;9(3):215-36. doi: 10.1038/nrd3028. Review.

3.

Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.

Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A.

Clin Pharmacol Ther. 2009 Oct;86(4):396-402. doi: 10.1038/clpt.2009.139. Epub 2009 Jul 22.

4.

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.

Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM.

Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.

5.

Physicochemical determinants of human renal clearance.

Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, El-Kattan A.

J Med Chem. 2009 Aug 13;52(15):4844-52. doi: 10.1021/jm900403j.

PMID:
19445515
6.

Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures.

Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN.

Nat Struct Mol Biol. 2009 Jun;16(6):652-7. doi: 10.1038/nsmb.1602. Epub 2009 May 10.

7.

Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule.

Lee WK, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H, Thévenod F.

Am J Physiol Renal Physiol. 2009 Jun;296(6):F1504-13. doi: 10.1152/ajprenal.90754.2008. Epub 2009 Apr 8.

PMID:
19357179
8.

Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells.

Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, Inui K.

J Pharmacol Exp Ther. 2009 Apr;329(1):185-91. doi: 10.1124/jpet.108.147918. Epub 2009 Jan 22.

9.

The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine.

Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, Sugiyama Y.

Drug Metab Dispos. 2009 Mar;37(3):555-9. doi: 10.1124/dmd.108.023911. Epub 2008 Dec 12.

10.

A competitive inhibitor traps LeuT in an open-to-out conformation.

Singh SK, Piscitelli CL, Yamashita A, Gouaux E.

Science. 2008 Dec 12;322(5908):1655-61. doi: 10.1126/science.1166777.

11.

Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.

Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P.

J Med Chem. 2008 Oct 9;51(19):5932-42. doi: 10.1021/jm8003152. Epub 2008 Sep 13.

PMID:
18788725
12.

Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.

Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, Taubert D.

Drug Metab Dispos. 2008 Aug;36(8):1616-23. doi: 10.1124/dmd.108.020826. Epub 2008 May 19.

13.

Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study.

Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, Faessel HM.

Clin Pharmacol Ther. 2008 Apr;83(4):567-76. Epub 2007 Oct 31.

PMID:
17971819
14.

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.

Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, Giacomini KM.

Clin Pharmacol Ther. 2008 Feb;83(2):273-80. Epub 2007 Jul 4.

15.

Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family.

Chen Y, Zhang S, Sorani M, Giacomini KM.

J Pharmacol Exp Ther. 2007 Aug;322(2):695-700. Epub 2007 May 10.

16.

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2006 Dec;80(6):565-81. Review.

PMID:
17178259
17.

Organic cation transporters are determinants of oxaliplatin cytotoxicity.

Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM.

Cancer Res. 2006 Sep 1;66(17):8847-57.

18.

Predicting in vivo drug interactions from in vitro drug discovery data.

Wienkers LC, Heath TG.

Nat Rev Drug Discov. 2005 Oct;4(10):825-33. Review.

PMID:
16224454
19.

A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2).

Zhang X, Shirahatti NV, Mahadevan D, Wright SH.

J Biol Chem. 2005 Oct 14;280(41):34813-22. Epub 2005 Aug 8.

20.

Unbiased descriptor and parameter selection confirms the potential of proteochemometric modelling.

Freyhult E, Prusis P, Lapinsh M, Wikberg JE, Moulton V, Gustafsson MG.

BMC Bioinformatics. 2005 Mar 10;6:50.

Supplemental Content

Support Center